TURLI ETIOLOGIYFLI JIGAR SIRROZIDA TGF-Β1 GENI POLIMORFIZMINING AHAMIYFTI HAMDA ULARNI KLIINK-NUTRITIV KO‘RSATKICHLAR BILAN BOG‘LIQLIGI
Kalit so‘zlar:
jigar sirrozi, genlar polimorfizmi, HBV+HDV, HCVAbstrak
Jigar sirrozining rivojlanishida fibrogenez jarayonlari hal qiluvchi ahamiyatga ega bo‘lib, ushbu xolatda transformatsiyalovchi o‘sish omili β1 — TGF-β1 muhim patogenetik mediatorlardan biri hisoblanadi. U jigar yulduzsimon hujayralari faollashuvi, ekstrasellyulyar matriks tarkibiy qismlari, xususan kollagen sintezining kuchayishi, fibroz to‘qima shakllanishi va jigar parenximasi arxitektonikasi buzilishida ishtirok etadi. Shu sababli TGF-β1 geni polimorfizmlari jigar sirrozining shakllanishi, kasallik og‘irligi, nutritiv еtishmovchilik va klinik asoratlar rivojlanishida genetik moyillik omili sifatida baholandi
##plugins.themes.default.displayStats.downloads##
Havolalar
1. Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol 2022; 7: 724-735 DOI: 10.1016/S2468-1253(22)00050-4
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. (2006) 44:217–31. doi: 10.1016/j.jhep.2005.10.013
3. Hagström, H. et al. Risk of cancer in biopsy-proven alcohol-related liver disease: a population-based cohort study of 3,410 persons. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2021.01.005 (2021); N’Kontchou, G. et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin. Gastroenterol. Hepatol. 4, 1062–1068 (2006)
4. Huang, D.Q., Mathurin, P., Cortez-Pinto, H. et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 20, 37–49 (2023). https://doi.org/10.1038/s41575-022-00688-6
5. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5: 245-266 DOI: 10.1016/S2468-1253(19)30349-8
6. Jiang JL, Qian JF, Xiao DH, Liu X, Zhu F, Wang J, Xing ZX, Xu DL, Xue Y, He YH. Relationship of familial cytochrome P450 4V2 gene mutation with liver cirrhosis: A case report and review of the literature. World J Clin Cases 2022; 10(28): 10346-10357
7. Kulkarni AV, Rabiee A, Mohanty A. Management of portal hypertension. J Clin Exp Hepatol. (2022) 12:1184–99. doi: 10.1016/j.jceh.2022.03.002; Kulkarni AV, Premkumar M, Reddy DN, Rao PN. The challenges of ascites management: An Indian perspective. Clin Liver Dis. (2022) 19:234–8. doi: 10.1002/cld.1209
8. Surial B, Wyser D, Byguelin C, Ramnrez-Mena A, Rauch A, Wandeler G. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Liver Int 2021; 41: 710-719
9. Zhai M, Long J, Liu S, Liu C, Li L, Yang L, Li Y, Shu B. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. Aging (Albany NY) 2021; 13: 279-300 DOI:10.18632/aging.104127
10. Punia V, Agrawal N, Bharti A, Mittal S, Chaudhary D, Mathur A, Anwar S, Chakravorty A. Association of TGF-β1 Polymorphism and TGF-β1 Levels With Chronic Hepatitis C and Cirrhosis: A Systematic Review and Meta-Analysis. Cureus. 2023 Jun 29;15(6):e41157. doi: 10.7759/cureus.41157. PMID: 37525796; PMCID: PMC10387134
